gepants

PreclinicalSmall molecule

IIRCCS San Raffaele Roma

gepants is one of 31 small molecule programs targeting Migraine. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MigraineActive, not recruiting

MigrainePreclinical

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Aimovig

Amgen

Preclinical

33 2

Emgality

Eli Lilly

Preclinical

19 3

Vyepti

Lundbeck

Preclinical

12 4

Savella

AbbVie

Preclinical

2 5

Bayer Aspirin

Bayer

Preclinical

2 6

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 7

Botox

RRevance Therapeutics, Inc.

Preclinical

9 8

Cervidil

Pfizer

Preclinical

1 9

Viagra

VViatris Specialty LLC

Preclinical

2 10

Pristiq

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Migraine1 trial

i-NEED: NEw migrainE Drugs Database

Recruiting·IIRCCS San Raffaele Roma··NCT07103694·2,641 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for gepants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gepants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gepants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IRCCS San Raffaele Roma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIRCCS San Raffaele Roma

gepants

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Migraine1 trial

References

Drug Info

Quick Facts

Related News